
HealthMore in Health→
TROP2 biomarker may identify lung cancer patients most likely to benefit from datopotamab deruxtecan
Key Takeaways
- Researchers used computational pathology to measure TROP2 at tumour-cell membranes and in cytoplasm.
- NMR-positive Dato-DXd recipients had median progression-free survival of 7.2 months versus 4.0 months for NMR-negative recipients.
- The same outcome separation was not reported in the docetaxel arm, supporting NMR as a potential predictive biomarker.
DE
DT Editorial Team··via nature.com